Related Experiment Video
Updated: Aug 14, 2026
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Development of coronary heart disease in familial hypercholesterolemia
H Mabuchi1, J Koizumi, M Shimizu
1Department of Internal Medicine, Kanazawa University School of Medicine, Japan.
Insights
Familial hypercholesterolemia patients develop coronary artery disease early. Myocardial infarction occurred in men by their 30s and women by their 40s, with early deaths in heterozygotes.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol.
- FH significantly increases the risk of premature cardiovascular disease.
- Understanding disease progression in FH is crucial for timely intervention.
Purpose of the Study:
- To investigate the development and progression of coronary artery disease (CAD) in patients with familial hypercholesterolemia.
- To determine the age of onset and severity of CAD in both heterozygous and homozygous FH patients.
- To establish regression models for coronary stenosis based on age.
Main Methods:
- Retrospective analysis of 10 homozygous and 692 heterozygous FH patients.
- Coronary angiographic evaluation in a subset of patients.
- Statistical analysis to determine regression equations between age and coronary stenosis index.
Main Results:
- Myocardial infarction (MI) affected 22% of male and 10% of female heterozygotes, starting in the 3rd and 4th decades, respectively.
- Coronary heart disease (CHD) caused death in 70% of deceased heterozygous patients, with a mean age of death significantly lower in males (54 years) than females (69 years).
- Regression analysis predicted angiographically detectable coronary artery stenosis after age 17 in males and 25 in females with heterozygous FH.
Conclusions:
- Coronary artery disease develops early in patients with familial hypercholesterolemia, particularly in males.
- Lipid-lowering therapy in heterozygous FH patients may be delayed until late adolescence based on predicted stenosis onset.
- Early identification and management strategies are essential for mitigating cardiovascular risk in FH.
Abstract:
We studied the development of coronary artery disease in 10 homozygous and 692 heterozygous patients with familial hypercholesterolemia. Seventy-five (22%) male heterozygotes and 35 (10%) female heterozygotes were affected by myocardial infarction, which was first noted in men in the 3rd decade of life and in women in the 4th decade of life. Thirty-eight (70%) out of the deceased 54 heterozygous patients died of coronary heart disease. The mean age at death was significantly less in male heterozygotes (54 years) than in female heterozygotes (69 years). Five homozygous and 105 male and 56 female heterozygous patients received coronary angiographic evaluation. The regression equations between age (X) and coronary stenosis index (Y) obtained by assigning score (0 to 5) to each of 15 coronary artery segments were Y = 1.57X - 20.43 (r = 0.956, p less than 0.05) in the homozygotes, Y = 0.52X - 9.11 (r = 0.438, p less than 0.001) in the male heterozygotes, and Y = 0.47X - 12.54 (r = 0.343, p less than 0.01) in the female heterozygotes. From these data, we can assume that coronary artery stenosis detectable by angiography will occur after 17 and 25 years of age in male and female heterozygotes, respectively, and the treatment of heterozygotes with lipid-lowering drugs can be delayed until late adolescence.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:30Atherosclerosis I: Introduction